BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
T cell differentiation
,
Ischemia
,
Prostate
,
Pharmacogenetics
,
Rapamycin
,
rs3825942
,
MYC
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
D PARP
Summary
General Info
Curated Studies
Most Correlated Studies
Hodgkin's lymphoma cell lines treated with kinase inhibitors perifosine, givinostat and sorafenib
Paternal poly(ADP-ribose) metabolism inhibition effects on embryonic gene expression
COLO320DM, ABC-1, U031, OVCAR-4, and RKO cells treated with TNKS1 and TNKS2 inhibitor G007-LK
Acute myeloid leukemia C1498 cells treated with PARP1 inhibitor PJ-34
HER2+ breast cancer brain metastases and HER2+ nonmetastatic primary breast cancers
Explore Curated Studies Results
Literature
Most Relevant Literature
The role of PARP1 in neurodegenerative diseases and aging.
Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative s…
PARP1 Inhibition and Effect on Burn Injury-Induced Inflammatory Response and Cardiac Function.
Nuclear Tkt promotes ischemic heart failure via the cleaved Parp1/Aif axis.
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associate…
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterio…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ